Index

Note: Page numbers in italics refer to Figures; those in bold to Tables.

Abilify see Aripiprazole
ACE inhibitors, 149
Actimmune, 53
Adverse drug reactions (ADRs), 9, 71, 72, 81, 84, 87–8, 97, 126
Alemtuzumab, 77
Allergan, 134
Alltrials movement, 147
Alosetron, 79
Alzheimer’s Disease Society, 122
American Medical Association (AMA), 12, 40, 55, 76, 127, 154
Amiodarone, 127
Amitriptyline, 28, 29, 89
Anaemia, 58
Anti-biotics, 4, 11, 22, 38, 42, 75, 76, 84, 86, 166
aminoglycosides, 75
use for viral infections, 75
use in bronchitis, 75
Anti-psychotic drugs, 10, 11
Apollo, 1
Aranesp see Erythropoietin-stimulating agents (ESAs)
Aripiprazole, 10, 12, 13, 74, 131
Asclepius, 1
Aspirin, 30, 54, 55, 89, 100, 121, 145, 167
Aspreva, 129
Association of the British Pharmaceutical Industry (ABPI), 135
Attention deficit disorder (ADD), 12, 17, 132
Attrition in drug development, 49
Australian Medicines Handbook, 94
Avastin, 43, 96, 97, 112, 116, 118, 119, 123
Avorn, Jerry, 59, 78, 89
AZT, 120
Benfluorex see Mediator scandal
Bevacizumab see Avastin
Bimatoprost, 21
Bipolar disorder, 10, 12, 29, 45, 76, 150
BMP-2, 15, 16, 88
BNF for Children, 94
Bone morphogenic protein 2 see BMP-2
Botox, 27–8, 131, 134, 139
Botulinum toxin see Botox
British National Formulary (BNF), 94
Bromfenac, 78
Buprenorphine, 74
Bupropion, 29
Campath-1H see Alemtuzumab
Captopril, 149
Caronia, Alfred, 139
Cateplaxy, 17, 139–41
Celgene, 7, 163
Cephalon, 17, 59, 60, 131, 137
Chloramphenicol, 83, 101
Class effects, 98
Compassionate access, 120–121
Cost, as a driver for Off-label Medicine, 121–3
Cures Within Reach, 122, 168
Cyclosporine, 25
Death of regulation, 2
Diagnosis, 44–6
Diclofenac, 100
Digitalis, 8
Digitoxin, 8
Dihydrotestosterone, 20
Dimebon, 51
Dimethyl fumarate, 26
Direct-to-Consumer (DTC) Advertising, 64–5
Doxycycline, 22, 23, 76, 165, 166
DrugRepurposing.info database, 3, 121
EMA, 49, 72, 117, 123, 126, 152, 160
Embrel, 68, 98, 164
Enoxaparin, 82
Epogen see Erythropoietin-stimulating agents (ESAs)
Erectile dysfunction, 2, 21, 83, 97, 108, 132, 165
Erythropoietin-stimulating agents (ESAs), 58
different doses, 81
European Medicines Evaluation Agency
(EMEA) see EMA
Factor VIIa, 13, 15, 81, 88, 120
FDA
does not regulate medical practice, 126
failed intervention in off-label medical
practice, 127
history of, 125
Orange Book, 66
Fenfluramine, 43, 79, 102, 103
Fen-Phen see Fenfluramine
Fentanyl, 73
Finasteride, 19–22, 67, 165, 166
Fluoroquinolones, 76, 88
Fluoxetine, 12, 28, 29, 51, 90
Francis Bacon, 19
Free speech, 138–42
Frovatriptan, 80
Gabapentin, 61–3, 68, 93, 131, 133, 137
Galantamine, 24
Gelbe Liste, 94
General Medical Council (GMC), 35, 38, 41, 46, 109, 112, 122, 123, 154
Genericisation, 65–8, 159, 166, 170
GlaxoSmithKline (GSK), 29, 64, 79, 84, 105, 106, 111, 130, 135, 147, 166
Gleason, Dr Peter, 140
Harkonen, Scott, 53
Herceptin, 117
Hippocrates, i, 30, 162, 163
Hippocratic Oath, xv, xvi, 1, 2, 36, 153
Hygieia, 1
Ibuprofen, 100
Indication creep see Therapeutic creep
Infliximab, 68, 98, 164
InterMune, 53
Investigational New Drug (IND), 49
Johnson & Johnson (J&J), 12, 25, 58, 131, 157
Latanoprost, 21
Latropride see Dimebon
Lemtra see Alemtuzumab
Leprosy, 6, 7, 43, 86, 161, 163
Levaquin (levofloxacin), 76, 151
Lucentis, 112, 118
Marijuana, medical use of, 64
Mediator scandal, 102, 152
Medicaid, 12, 115, 157, 169
Medical myths, 101–3
Medical Professional guidelines, 38–41
Medicare, 13, 34, 73, 115, 116, 131, 157, 169
Merck, 19, 20, 54–6, 99, 131, 145, 165, 166
Metformin, 31, 96, 168
Michael Jackson, 83
Michael J Fox Foundation, 122
Minoxidil, 21
Modafinil, 17, 59, 60, 67, 68, 74, 131
Multiple sclerosis (MS), 26–7, 29, 60, 77
Naproxen, 55, 100
Narcolepsy, 17
National Center for Advancing Translational
Sciences (NCATS), 169
National Institute for Health and Care
Excellence (NICE), 10, 97, 115, 117–20, 154, 157
Neurontin see Gabapentin
Neuropharm, 51
New Drug Application (NDA), 49
Niacin, 16, 17
NovoSeven see Factor VIIa
NSAID gastropathy, 101
Off-label Medicine
commercial development of generic
products, 164–7
fines (for promotion), 130–134
generic medicine, 136–8
is not a trial, 160–162
measuring outcomes, 159–60
patient awareness, 41
poor evidence, 13
statistics, 4
by therapeutic class, 4
types of, 3
use in oncology, 13
use in psychiatry, 9
Olanzapine, 10–12, 87, 131, 150
Olsen, Gwen, 63, 74
Oncology, 4, 96, 97, 115
Ondansetron, 79
Orphan drugs, 56–61, 68
Orphan Medical, 139
Oxycodone, 73, 131
Paroxetine (Paxil), 84–5
Patents, 65–8
Pfizer, 2, 21, 22, 49, 51, 61, 62, 79, 130, 131, 132, 133, 139, 145–7, 165
Pharmacovigilance, 84, 123, 128, 138, 153, 163, 164, 165, 174
Phentermine, 43, 79
PhRMA, 61
Physician’s Desk Reference, 94
Post-traumatic stress disorder (PTSD), 10–11, 64, 84, 94, 132
Prescription Medicines Code of Practice Authority (PMCPA), 135
Pricing, 156–9, 173–4
Propofol, 83
Proscar see Finasteride
Proton-pump inhibitors, 97
Provenge, 52
Prozac see Fluoxetine
Pseudohermaphroditism, 19, 20, 21
Psoriasis, 25–7, 99
Pulmonary hypertension, 22, 79, 83, 103
Quetiapine, 11, 12, 92, 93, 94, 132
Raloxifene, 23, 24
Reimbursement, 105–23, 156–9, 173–4
Relatedness, of diseases and drugs, 96
Revatio, 165
Risperidone, 10–12, 87, 92, 93, 131
Rofecoxib see Vioxx
Rote Liste, 94
Sildenafil see Viagra
Social Impact Bonds (SIBs), 168
Sodium oxybate see Xyrem
Sofosbuvir see Solvadi
Solvadi, 47, 114
SSRIs, 12, 28, 29, 51, 84, 86, 90
Statins, 16, 98, 145, 170
Stents, 72
Tamiflu, 151
Tamoxifen, 23
Testosterone, 20, 97
Tetracyclines, 22, 84
Thalidomide, 5–8, 30, 86, 125, 143, 161, 163
Therapeutic creep, 97, 147
Tiagabine, 76
Topiramate, 29
Torcetrapib, 49
Tricyclic anti-depressants
  safety issues in diabetic neuropathic pain, 75
Velcade, 157
Vernalis, 80
Viagra, 2, 21, 22, 108, 132, 165
Vioxx, 54–6, 99, 100, 101, 131
Whistleblowers, 134
Withering, William, 8
Xyrem, 64, 139–41, 146, 158
Zombies, 10